Policy & Regulation
Mogrify, Astellas Forge Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss
6 July 2022 - - UK-based biopharmaceutical company Mogrify Ltd and Japan-based regenerative medicine specialist Astellas Pharma Inc. (TSX: 4503) have executed a collaborative research agreement on&nbs...
Inmagene and HUTCHMED report dosing of first participant in global Phase I trial of investigational OX40 antagonistic monoclonal antibody IMG-007
6 July 2022 - Inmagene Biopharmaceuticals, a developer of novel therapeutics for immunology-related diseases, reported on Wednesday that in partnership with biopharmaceutical company HUTCHMED (China) ...
Mogrify signs collaborative research agreement with Astellas
6 July 2022 - Mogrify Limited, a UK-based biopharmaceutical company, announced on Tuesday that it has signed a collaborative research agreement with Japan-based Astellas for in vivo regenerative medic...
Lyra Therapeutics names new chief medical officer
6 July 2022 - Lyra Therapeutics, Inc. (Nasdaq: LYRA), a US-based clinical-stage therapeutics company, announced on Tuesday that it has named Richard Nieman, MD as its new chief medical officer, effect...
EditForce signs License Agreement with Mitsubishi Tanabe Pharma Corporation
6 July 2022 - Japan- based drug development company EditForce, Inc. announced on Tuesday that it has signed a License Agreement with Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC) to research...
US FDA Lifts Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
5 July 2022 - - The US Food and Drug Administration has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic...